Improved PFS in Advanced Kidney Cancer With Antiangiogenic Combination
https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — SAN FRANCISCO — Dual antiangiogenic therapy for previously treated kidney cancer significantly improved progression-free survival (PFS) compared with a single drug, a large randomized trial showed. Median PFS improved by 10.7…
